ALK Inhibitors and CD47 Blockade in Cancer Treatment
Author Information
Author(s): Federica Malighetti, Matteo Villa, Mario Mauri, Simone Piane, Valentina Crippa, Ilaria Crespiatico, Federica Cocito, Elisa Bossi, Carolina Steidl, Ivan Civettini, Chiara Scollo, Daniele Ramazzotti, Carlo Gambacorti-Passerini, Rocco Piazza, Luca Mologni, Andea Aroldi
Primary Institution: Department of Medicine and Surgery, University of Milano-Bicocca
Hypothesis
Can combining ALK inhibitors with anti-CD47 monoclonal antibodies enhance phagocytosis in ALK-driven malignancies?
Conclusion
The combination of ALK inhibitors and anti-CD47 antibodies significantly enhances phagocytosis in both sensitive and resistant ALK-driven cancers.
Supporting Evidence
- ALK inhibitors increased CALR expression in both sensitive and resistant ALK+ cancer cells.
- The combination of ALK inhibitors and anti-CD47 mAb significantly enhanced phagocytosis compared to anti-CD47 alone.
- Continuous exposure to TKIs resulted in CD47 upregulation over time.
Takeaway
This study shows that using certain cancer drugs together can help the immune system eat cancer cells better, even when the cancer is tough to treat.
Methodology
The study used flow cytometry and co-culture assays to evaluate the effects of ALK inhibitors and anti-CD47 antibodies on phagocytosis in cancer cell lines.
Limitations
The study lacks in vivo validation and relies on preclinical models.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website